GGrantIndex
Sort

15,440 grants matching organoids

Fibroblast orchestration of the immune response in pancreatic cancer

$786,440
Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · U01 · FY2024 · CA

Establishment of a causal link between AD and L1 retrotransposons

$786,116
Alysson R. Muotri · University Of California, San Diego · R01 · FY2022 · AG

Single-cell multi-region dissection of AD-pathogen interactions for HSV-1 and CMV

$786,088
Manolis Kellis · Massachusetts Institute Of Technology · R01 · FY2023 · AG

Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids

$785,933
Yanling Wang · Rush University Medical Center · R01 · FY2022 · AG

Revealing the roles of HSV1 lytic and latent transcripts in AD pathogenesis and therapy

$785,854
Michael G Rosenfeld · University Of California, San Diego · R01 · FY2024 · AG

Modeling diabetes using an integrated plate system

$785,782
James M Wells · Cincinnati Childrens Hosp Med Ctr · UG3 · FY2019 · DK

Identifying Factors Regulating Medium Spiny Neuron Differentiation or Maintenance as Therapeutic Targets for Huntington's Disease using Induced Pluripotent Stem Cells

$785,686
Lisa M. Ellerby · Buck Institute For Research On Aging · R01 · FY2025 · NS

Metabolic Landscape of the Aging Lung

$785,329
Jarrod W. Barnes · University Of Alabama At Birmingham · R01 · FY2022 · HL

Metabolic Landscape of the Aging Lung

$785,329
Jarrod W. Barnes · University Of Alabama At Birmingham · R01 · FY2023 · HL

Metabolic Landscape of the Aging Lung

$785,329
Jarrod W. Barnes · University Of Alabama At Birmingham · R01 · FY2021 · HL

Human Isogenic Organoid Models of Genetic Forms of Autism to Identify Convergent and Divergent Pathomechanisms in Autism

$785,119
Eugene Wei-Ming Yeo · University Of California, San Diego · R01 · FY2025 · MH

Regulation of HIV latency by microglial-neuronal interactions

$784,868
Jonathan Karn · Case Western Reserve University · R01 · FY2023 · DA

2/2 Discovery and validation of neuronal enhancers associated with the development of psychiatric disorders

$784,830
Daniel H Geschwind · University Of California Los Angeles · U01 · FY2020 · MH

A new brain organoid model for NeuroHIV and the impact of opioids

$784,742
Alysson R. Muotri · University Of California, San Diego · R01 · FY2025 · DA

Establishment of a causal link between AD and L1 retrotransposons

$784,679
Alysson R. Muotri · University Of California, San Diego · R01 · FY2023 · AG

Assessing Genomic, Regulatory and Transcriptional Variation at Single Nuclei Resolution in the Brains of Individuals with Autism Spectrum Disorder

$784,665
Tomasz Nowakowski · University Of California, San Francisco · R01 · FY2025 · MH

Post-transcriptional modification in esophageal basal cells.

$784,280
Jianwen Que · Columbia University Health Sciences · R01 · FY2025 · DK

Spectinomycin analogs for NTM infections

$784,246
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2023 · AI

Enhancer RNAs in brain gene regulation and Alzheimer's disease

$783,820
Wenbo Li · University Of Texas Hlth Sci Ctr Houston · R01 · FY2023 · AG

Intestinal microbiota-mediated rotavirus vaccine failure

$783,735
Andrew T Gewirtz · Georgia State University · R01 · FY2025 · AI

Intestinal microbiota-mediated rotavirus vaccine failure

$783,735
Andrew T Gewirtz · Georgia State University · R01 · FY2024 · AI

Intestinal microbiota-mediated rotavirus vaccine failure

$783,735
Andrew T Gewirtz · Georgia State University · R01 · FY2023 · AI

Hydrogel-enabled self-assembled human brain organoids for neurotoxicity applications

$783,533
Connie S Lebakken · Stem Pharm, Inc. · R44 · FY2022 · ES

Cell-type-specific NRXN1alpha alternative splicing changes in psychiatric disease

$783,464
Gang Fang · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · MH

Lung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II Cells

$783,378
Paul J Wolters · University Of California, San Francisco · R01 · FY2024 · HL